Psychemedics (PMD)

Executive Summary

Psychemedics Corporation (NASDAQ: PMD) is a specialized biotechnology company focused on hair drug testing for drugs of abuse. Its proprietary hair analysis technology offers a detection window of up to 90 days, significantly longer than traditional urine-based tests. The company primarily serves employers for pre-employment and workplace testing, as well as law enforcement agencies, schools, and other organizations. Founded in 1986 and headquartered in Dallas, Texas, Psychemedics operates as a public company with a market capitalization of approximately $15.7 million. The company’s business model centers on providing laboratory testing services directly and through distribution partners, with testing panels covering substances such as cocaine, marijuana, opiates, amphetamines, and PCP. Despite being a niche player in the forensic toxicology space, Psychemedics faces challenges from competing testing methods and evolving drug legalization trends, particularly regarding cannabis. The company's financial performance has been volatile, with recent revenue declines and net losses, reflecting industry headwinds and pricing pressures. However, its established brand and court-admissible results provide a competitive moat in safety-sensitive industries.

Upcoming Catalysts (preview)

• Q3 2026Large New Client Win or Government Contract30% success
• Q4 2026Expansion into Cannabis Testing Services20% success
• TBDOperational Efficiency or Cost Reduction Initiatives40% success